UK markets closed

Cara Therapeutics, Inc. (CARA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.9071+0.1083 (+13.56%)
At close: 04:00PM EST
0.9500 +0.04 (+4.73%)
After hours: 08:00PM EST

Cara Therapeutics, Inc.

4 Stamford Plaza
9th Floor 107 Elm Street
Stamford, CT 06902
United States
203 406 3700
https://www.caratherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees106

Key executives

NameTitlePayExercisedYear born
Mr. Christopher A. PosnerPresident, CEO & Director1.2MN/A1970
Mr. Ryan D. MaynardChief Financial Officer511.7kN/A1969
Dr. Joana Goncalves M.D.Chief Medical Officer747.25kN/A1974
Dr. Derek T. Chalmers D.Sc., Ph.D.Co-Founder & Senior Advisor580.93kN/A1964
Dr. Iris Francesconi Ph.D.Chief Strategy Officer & Head of Investor RelationsN/AN/AN/A
Mr. Scott M. TerrillionChief Compliance Officer, General Counsel & Corporate Secretary689.63kN/A1963
Ms. Beth Weinberg R.Ph.Senior Vice President of Regulatory Affairs & QAN/AN/AN/A
Mr. Matthew MurphyManager of Investor RelationsN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Cara Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate, including Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. Cara Therapeutics, Inc. has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. and Winhealth Pharma for the co-development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis in China; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. The company was incorporated in 2004 and is based in Stamford, Connecticut.

Corporate governance

Cara Therapeutics, Inc.’s ISS governance QualityScore as of 1 February 2024 is 6. The pillar scores are Audit: 4; Board: 4; Shareholder rights: 7; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.